Antihypertensive efficacy of moxonidine in primary care: A 'real-life' study

International Journal of Clinical Practice

Volumn 57, Issue 6, 2003, Pages 479-482

  Schachter, M ^a   Mitchell, G ^b   Niziol, Christie ^b   Abhyankar, B A ^c  

^a NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^b Decision Resources Group   (United Kingdom)

^c Solvay Healthcare Ltd   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CLONIDINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; METHYLDOPA; MOXONIDINE; RESERPINE;

ADULT; AGED; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; BLOOD PRESSURE REGULATION; DEPRESSION; DRUG EFFICACY; DRUG MECHANISM; DRUG TOLERABILITY; FEMALE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MEDICAL PRACTICE; MONOTHERAPY; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RETROSPECTIVE STUDY; SEDATION; SIDE EFFECT; XEROSTOMIA;

AGED; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CROSS-SECTIONAL STUDIES; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYPERTENSION; IMIDAZOLES; MALE; MIDDLE AGED; PRIMARY HEALTH CARE; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 0041562510     PISSN: 13685031     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. MacMahon S, Peto R, Cutler J et al. Blood pressure, stroke, and coronary heart disease. Part 1, Prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet 1990; 335: 765-774.
2. Collins R, Peto R, MacMahon S et al. Blood pressure, stroke, and coronary heart disease. Part 2, Short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet 1990; 335: 827-838.
3. Joint National Committee. Sixth National Report of the Joint National Committee on prevention, detection, evaluation and treatment of high blood pressure (JNC VI). Arch Intern Med 1997; 157: 2413-2446.
4. Guidelines Subcommittee. 1999 World Health Organization-International Society of Hypertension. Guidelines for the management of hypertension. J Hypertens 1999; 17: 151-183.
5. Colhoun HM, Dong W, Poulter NR. Blood pressure screening, management and control in England: results from the health survey for England 1994. J Hypertens 1998; 16: 747-752.
6. Primatesta P, Brookes M, Poulter NR. Improved hypertension management and control: results from the Health Survey for England 1998. Hypertension 2001; 38: 827-832.
7. Materson BJ, Reda DJ, Cushman WC. Department of Veterans Affairs single-drug therapy of hypertension study. Revised figures and new data. Department of Veterans Affairs cooperative study group on antihypertensive agents. Am J Hypertens 1995; 8: 189-192.
8. Hansson L, Zanchetti A, Carruthers SG et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT study group. Lancet 1998; 351: 1755-1762.
9. Ramsay L, Williams B, Johnston G et al. Guidelines for management of hypertension: report of the third working party of the British Hypertension Society. J Hum Hypertens 1999; 13: 569-592.
10. Waters J, Ashford J, Jager BA et al. Use of moxonidine as initial therapy and in combination in the treatment of essential hypertension: results of the TOPIC (Trial of Physiotens in Combination) study. J Clin Basic Cardiol 1999; 2: 219-224.
11. Trieb G, Jager BA, Hughes PR et al. Long-term evaluation of the antihypertensive efficacy and tolerability of the orally acting imidazoline I1 receptor agonist moxonidine in patients with mild-to-moderate essential hypertension. Eur J Clin Res 1995; 7: 227-240.
12. Prichard BN, Graham BR. Effective antihypertensive therapy: blood pressure control with moxonidine. J Cardiovasc Pharmacol 1996; 27(suppl 3): S38-S48.
13. Kuppers, HE, Jager, BA, Luszick, JH et al. Placebo-controlled comparison of the efficacy and tolerability of once- daily moxonidine and enalapril in mild-to-moderate essential hypertension. J Hypertens 1997; 15: 93-97.
14. Wolf R. The treatment of hypertensive patients with a calcium antagonist or moxonidine: a comparison. J Cardiovasc Pharmacol 1992; 20(suppl 4): s42-s44.
15. Prichard BN, Simmons R, Rooks M et al. A double-blind comparison of moxonidine and atenolol in the management of patients with mild-to-moderate hypertension. J Cardiovasc Pharmacol 1992; 20: s45-s49.
16. Frei M, Kuster L, Gardosch von Krosigk P et al. Moxonidine and hydrochlorothiazide in combination: a synergistic antihypertensive effect. J Cardiovasc Pharmacol 1994; 24(suppl 1): s25-s28.
17. Lotti G, Gianrossi R. Moxonidine vs captopril in minor to intermediate hypertension: double-blind study of effectiveness and tolerance. Fortschr Med 1993; 111: 429-432.
18. Planitz V. Crossover comparison of moxonidine and clonidine in mild to moderate hypertension. Eur J Clin Pharmacol 1984; 27: 147-152.
19. Planitz V. Comparison of moxonidine and clonidine HCl in treating patients with hypertension. J Clin Pharmacol 1987; 27: 46-51.
20. Kuppers HE, Jager BA, Luszick JH et al. Placebo-controlled comparison of the efficacy and tolerability of once- daily moxonidine and enalapril in mild-to-moderate essential hypertension. J Hypertens 1997; 15: 93-97.
21. Chrisp P, Faulds D. Moxonidine: a review of its pharmacology, and therapeutic use in essential hypertension. Drugs 1992; 44: 993-1012.
22. British Cardiac Society, British Hyperlipidaemia Association, British Hypertension Society, and British Diabetic Association. Joint British recommendations on prevention of coronary heart disease in clinical practice: summary. BMJ 2000; 320: 705-708.
23. DIN-Link database. Compufile. www.compufile.co.uk
24. Warner JO. Review of prescribed treatment for children with asthma in 1990. BMJ 1995; 311: 663-666.
25. Plumb JM, Guest JF. Annual cost of erectile dysfunction to UK society. Pharmacoeconomics 1999; 16: 699-709.
26. Dunn RL, Donoghue JM, Ozminkowski RJ et al. Longitudinal patterns of antidepressant prescribing in primary care in the UK: comparison with treatment guidelines. J Psychopharmacol 1999; 13: 136-143.
27. Guest JF, Munro VL. A comparison of the economic impact on the National Health Service of ramipril and enalapril in the treatment of essential hypertension. Br J Med Econ 1996; 10: 303-314.
28. Martin RM, Hilton SR, Kerry SM. The impact of the October 1995 'pill scare' on oral contraceptive use in the United Kingdom: analysis of a general practice database. Fam Pract 1997; 14: 279-284.
29. Deary AJ, Schumann AL, Murfet H et al. Double-blind placebo-controlled crossover comparison of five classes on antihypertensive drugs. J Hypertens 2002; 20: 771-777.
30. Ross SD, Akhras KS, Zhang S et al. Discontinuation of antihypertensive drugs due to adverse events: a systematic review and meta-analysis. Pharmacotherapy 2001; 21: 940-953.